PE
ROIV icon

Point72 Europe’s Roivant Sciences ROIV Stock Holding History

Point72 Europe’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$150K Buy
+9,891
New +$122K 0.01% 229

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Point72 Europe's ROIV Position: Q3 2025 in Review

Point72 Europe opened a new position in Roivant Sciences (ROIV) in Q3 2025: 9,891 shares worth $150K. The stake represents 0.01% of the portfolio and ranks #229 among its holdings.

337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Point72 Europe held 9,891 shares of Roivant Sciences worth $150K as of Q3 2025.
  • Roivant Sciences was a new Point72 Europe position in Q3 2025.
  • Roivant Sciences made up 0.01% of Point72 Europe's portfolio in Q3 2025, its #229 holding.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.